Zai Lab (ZLAB) Q3 2024 earnings summary

Executive summary

• Net product revenue grew 47% year-over-year to $101.8 million in Q3 2024, driven by VYVGART, ZEJULA, and NUZYRA sales, with strong commercial execution and pipeline progress including KarXT and ZL-1310.

• Net loss improved by 40% year-over-year to $41.7 million, with operational efficiency gains and a strong cash position of $716.1 million as of September 30, 2024.

• Expanded late-stage pipeline and achieved regulatory milestones, including NMPA approvals for VYVGART Hytrulo (CIDP), XACDURO, and positive KarXT schizophrenia data.

• Year-to-date 2024 product revenue reached $289.1 million, a 44% increase year-over-year.

• Company continues to invest in R&D and commercial expansion, with multiple product launches and regulatory submissions planned through 2025.

Financial highlights

• Q3 2024 net product revenue: $101.8 million (+47% Y/Y); nine-month revenue: $289.1 million (+44% Y/Y).

• VYVGART Q3 revenue: $27.3 million (+458% Y/Y); ZEJULA: $48.2 million (+16% Y/Y); NUZYRA: $10.0 million (+82% Y/Y); QINLOCK: $8.6 million (+52% Y/Y).

• Net loss for Q3 2024 was $41.7 million, a 40% improvement from Q3 2023.

• Adjusted loss from operations: $48.2 million in Q3 2024, down 19% year-over-year.

• Cash and equivalents: $716.1 million at quarter end.

Outlook and guidance

• Expect continued revenue growth and narrowing losses, with profitability targeted by end of 2025.

• FY 2024 VYVGART sales guidance set at over $80 million; potential to surpass $1 billion annually in China.

• Three product launches in China expected by end of 2024: XACDURO, VYVGART Hytrulo, and AUGTYRO.

• Up to four regulatory submissions to NMPA in next six months, including KarXT NDA for schizophrenia in early 2025; bemarituzumab results expected soon.

• 2028 vision includes over $2 billion revenue and expanding operating margins.